A high-performance blood-based DNA methylation test for early detection of gastrointestinal cancers. Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA genomic ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk for ...

Early and sustained clearance of circulating tumor DNA (ctDNA) was strongly associated with achieving pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving ...

ctDNA monitoring post-surgery can identify high recurrence risk in skin cancer, aiding treatment decisions. Droplet digital PCR (ddPCR) effectively detects minimal residual disease (MRD) in melanoma ...

ctDNA changes at 1 month post-treatment correlate with progression-free and overall survival in dMMR/MSI-H mCRC patients, especially with avelumab treatment. Baseline ctDNA levels were not associated ...

Patients with detectable ctDNA before treatment had a shorter duration of clinical benefit and shorter overall survival. Having detectable circulating tumor DNA (ctDNA) before treatment is associated ...

Please provide your email address to receive an email when new articles are posted on . Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of ...

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA. We are at a critical crossroads for the clinical use of ctDNA ...

Ultrasensitive circulating tumor DNA (ctDNA) testing may help identify women with triple-negative breast cancer who are at either a very high or very low risk for recurrence after surgery, new ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is circulating tumor DNA, often called ctDNA, which is gaining attention in ...